Clinical Trial Update: Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on etanercept (TNFR:Fc) in children with Juvenile Rheumatoid Arthritis (Phase 2/Phase 3) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Rheumatoid Arthritis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Amgen | Conditions: Juvenile Rheumatoid Arthritis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-08-02